Aducanumab

Department of Health and Social Care written question – answered am ar 2 Gorffennaf 2021.

Danfonwch hysbysiad imi am ddadleuon fel hyn

Photo of Imran Ahmad Khan Imran Ahmad Khan Ceidwadwyr, Wakefield

To ask the Secretary of State for Health and Social Care, what recent assessment his Department has made of the potential merits of the Alzheimer’s drug Aduhelm.

Photo of Nadine Dorries Nadine Dorries Minister of State (Department of Health and Social Care)

The Medicines and Healthcare products Regulatory Agency (MHRA) is monitoring regulatory developments regarding Aducanumab (Aduhelm). We are unable to formally comment on any product that is not approved for use in the United Kingdom due to commercial and market sensitivities surrounding the approval process of a product. As with all other treatments for life threatening or debilitating conditions, the MHRA will ensure a thorough and expedited assessment of this medicine.

Does this answer the above question?

Yes1 person thinks so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.